Literature DB >> 10408417

Detection of regional melanoma metastases by ultrasound B-scan, cytology or tyrosinase RT-PCR of fine-needle aspirates.

C Voit1, A Schoengen, M Schwürzer, L Weber, T Mayer, T M Proebstle.   

Abstract

Physical examination and ultrasound B-scan screening are important follow-up procedures in melanoma patients with regional disease. However, they do not allow definite diagnosis of suspicious lesions. Fine-needle aspiration cytology (FNAC) enhances the diagnostic accuracy in such patients but, unfortunately, reaches its technical limits, particularly when very small or necrotic lesions are examined. We therefore tested whether tyrosinase reverse transcription polymerase chain reaction (RT-PCR) of fine-needle aspirates (FNA-PCR) could help to increase diagnostic sensitivity. With clinical follow-up in 69 melanoma patients 81 regional lymph nodes were detected by ultrasound B-scan examination, nine of whom appeared to be palpable. Technically, FNAC was successful in all 81 lymph nodes, while FNA-PCR failed to obtain RNA at detectable levels in two lymph nodes of two patients. Of 79 lesions which have been completely evaluated by B-scan, FNAC and FNA-PCR, 44 proved to be melanoma metastases by histopathology, while the remaining 35 lesions were finally classified as non-specific lymph nodes. Of the 44 melanoma metastases 80% (n = 35) have been detected by B-scan, 90% (n = 39) by FNAC and 100% (n = 44) by FNA-PCR (P < 0.05 vs FNAC, P < 0.005 vs B-scan). In the subclass of lesions with diameters below 10 mm the sensitivities were 72% (n = 13), 78% (n = 14) and 100% (n = 18) respectively. In 35 regional lymph nodes classified as benign lesions, FNAC was always negative while FNA-PCR produced one positive result. Neither of these methods did produce false positive results in 15 control lymph nodes of non-melanoma patients. We conclude, that FNA-PCR might have superior sensitivity as compared to FNAC or ultrasound B-scan, particularly in melanoma lesions with diameters below 10 mm.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408417      PMCID: PMC2363104          DOI: 10.1038/sj.bjc.6690580

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients.

Authors:  F A Jung; A C Buzaid; M I Ross; K V Woods; J J Lee; M Albitar; E A Grimm
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

2.  Sonographic detection and fine-needle aspiration biopsy of nonpalpable recurrent or metastatic melanoma in subcutaneous tissues.

Authors:  B D Fornage; J G Lorigan
Journal:  J Ultrasound Med       Date:  1989-08       Impact factor: 2.153

3.  [Fine needle aspiration cytology of metastatic malignant melanoma. Improvement of results with ultrasound control].

Authors:  A Schoengen; T Binder; S Faiss; L Weber; U Zeelen
Journal:  Hautarzt       Date:  1993-11       Impact factor: 0.751

4.  Expression of the mouse tyrosinase gene during embryonic development: recapitulation of the temporal regulation in transgenic mice.

Authors:  F Beermann; E Schmid; G Schütz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

5.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction.

Authors:  B Smith; P Selby; J Southgate; K Pittman; C Bradley; G E Blair
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

6.  Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region.

Authors:  S Ponnazhagan; L Hou; B S Kwon
Journal:  J Invest Dermatol       Date:  1994-05       Impact factor: 8.551

7.  Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: a clinical and pathologic correlation of 298 cases.

Authors:  M D Perry; H F Seigler; W W Johnston
Journal:  J Natl Cancer Inst       Date:  1986-11       Impact factor: 13.506

8.  Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma.

Authors:  X Wang; R Heller; N VanVoorhis; C W Cruse; F Glass; N Fenske; C Berman; J Leo-Messina; D Rappaport; K Wells
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

9.  Hematogenous spread of malignant melanoma cells in different stages of disease.

Authors:  P Brossart; U Keilholz; M Willhauck; C Scheibenbogen; T Möhler; W Hunstein
Journal:  J Invest Dermatol       Date:  1993-12       Impact factor: 8.551

10.  Functional analysis of alternatively spliced tyrosinase gene transcripts.

Authors:  G Müller; S Ruppert; E Schmid; G Schütz
Journal:  EMBO J       Date:  1988-09       Impact factor: 11.598

View more
  2 in total

1.  FNA diagnosis of malignant melanoma-recurrent and metastatic disease.

Authors:  Kiran Alam; Anshu Jain; Meher Aziz; Aroonima Misra
Journal:  BMJ Case Rep       Date:  2012-11-14

2.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.